( September 11, 2025, 3:01 PM EDT) -- NEW ORLEANS — Companies representing the interests of drug compounders tell the Fifth Circuit U.S. Court of Appeals in an opening brief that a Texas district court erred in awarding summary judgment to the U.S. Food and Drug Administration in a dispute over whether the agency violated the law when it removed semaglutide, an FDA-approved drug for diabetes and weight loss, from the agency’s drug shortage list....